The Top 75: MicroMass Communications

Share this article:
After a down year in 2009 and a slow start to 2010, business picked up considerably for MicroMass Communications during the second half of  the year. Though he declines to reveal specifics, president Jay Bigelow reports 2010 revenue was up overall compared to 2009. The agency landed five new wins in a row at the end of the year, and momentum has continued with Q1 2011 revenue up 50% compared to Q4 2010.
Based in Cary, NC, MicroMass is a full-service agency deeply rooted in behavioral science. Bigelow says applying behavioral science helps the agency provide all clients with smarter approaches, and he adds that it will become the “prerequisite to good marketing” in the world of personalized medicine.
The agency landed 12 wins last year, including great organic growth from Auxilium (preapproval work in Xiaflex); Bayer (two devices); Novartis (Sandostatin); United Therapeutics (a patient education and support program for its PAH franchise); and Merck, (a global assignment for Gardasil).  
New clients included New American Therapeutics, which awarded AOR work spanning corporate development for the newly established company and promotion of its sole product—cold sore treatment Denavir. Physicians Pharmacy Alliance, which Bigelow says has never done any marketing at all, also selected MicroMass as AOR.
Other wins included Takeda's Edarbi (blood pressure); Talecris' Gamunex (CIDP, PI, ITP); digital work for B. Braun; and global work for Quintiles. Promotion stopped on Shire's Fosrenol and Merck's Singulair.
“There's forward momentum in the kinds of work we're doing and the size of work we're doing,” Bigelow says. “Takeda is a great example. Edarbi is head and shoulders above anything that's out there, and we built a platform they can use for a long time.”
Bigelow adds that insight into metabolic mindset (on which MicroMass had released a white paper) contributed to the Edarbi win.
In addition to the oft-cited industry challenges (regulatory, etc.), Bigelow believes the general approach to marketing for the life sciences can be greatly improved.
“The challenge is in getting marketing people to understand that companies are launching brands not molecules,” he explains. “Marketing professionals need to do a better job educating clients on what marketing is about and the value of creating strong brands. P&G has a strong discipline of teaching good marketing, but that philosophy and approach doesn't permeate pharma. I think we'll see successful companies have more and more of that.”

Somewhat surprisingly, given the agency's location, Bigelow says he hasn't had trouble recruiting talent. Significant investment was made in senior talent last year, including Joe Soto, EVP account management and John Hamilton, SVP group account director; and Connie Mester, business development director. Don Martiny, VP group creative director, is among 2011 new hires.

Page 1 of 2
Share this article:

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.